Search Result
14 search results for Histiocytic Neoplasms
NCCN Guidelines Histiocytic Neoplasms
NCCN Guidelines Histiocytic Neoplasms, NCCN clinical practice guidelines in oncology – Histiocytic Neoplasms
https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdfErdheim-Chester Disease
NCCN clinical practice guidelines in oncology – Histiocytic Neoplasms
https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdfLangerhans Cell Histiocytosis
NCCN clinical practice guidelines in oncology – Histiocytic Neoplasms
https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdfRosai-Dorfman Disease
NCCN clinical practice guidelines in oncology – Histiocytic Neoplasms
https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdfPermission to Cite or Use NCCN Content
Hepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma, Transplantation Hematopoietic Growth Factors Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin, Factors Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer, Transplantation Hematopoietic Growth Factors Hepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer Lung Cancer Screening Management
https://www.nccn.org/guidelines/permission-to-cite-or-use-nccn-contentTransparency Process
Histiocytic Neoplasms Panel, Version: 1.2023 ( Histiocytic Neoplasms ) Date: 2022-12-02 Transparency Panel Disclosures/Attendance Version: 1.2022 ( Histiocytic Neoplasms ) Date: 2021-12-16 Transparency, Panel Disclosures/Attendance Version: 3.2024 ( Uterine Neoplasms ) Date: 2024-06-20, ( Uterine Neoplasms ) Date: 2024-02-29 Transparency Panel Disclosures/Attendance
https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendationsGuidelines Panels
Cancers Panel Histiocytic Neoplasms, Myeloproliferative Neoplasms Panel
https://www.nccn.org/guidelines/guidelines-panels-and-disclosure/disclosure-panelsTreatment by Cancer Type
Version: 3.2024 Histiocytic Neoplasms, Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Version: 2.2024 Myeloproliferative Neoplasms, Neoplasms Version: 3.2024 Vaginal Cancer
https://www.nccn.org/guidelines/category_1Submission Request Form
Hepatobiliary Cancers - 1.2023 Hepatocellular Carcinoma - 3.2024 Histiocytic Neoplasms - 2.2024 Hodgkin, Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions - 2.2024 Myeloproliferative Neoplasms - 2.2024, Uterine Neoplasms - 3.2024 Vaginal Cancer - 2.2025 Vulvar Cancer - 4.2024 Waldenström
https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-formResume Screening
Hepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma, Mesothelioma: Pleural Multiple Myeloma Myelodysplastic Syndromes Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Myeloproliferative Neoplasms Neuroblastoma, and Thymic Carcinomas Thyroid Carcinoma Uterine Neoplasms Vaginal Cancer Vulvar Cancer, Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Neoplasms Nasopharyngeal Cancer
https://www.nccn.org/covid-19/resume-screeningGuidelines With Evidence Blocks
Version 4.2024 Hepatocellular Carcinoma Version 3.2024 Histiocytic Neoplasms Version, Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Version 2.2024 Myeloproliferative Neoplasms Version 2.2024 Neuroendocrine and Adrenal Tumors, Version 1.2024 Thyroid Carcinoma Version 4.2024 Uterine Neoplasms Version 3.2024
https://www.nccn.org/guidelines/guidelines-with-evidence-blocksChemotherapy Order Templates Reviewer Acknowledgement
Roswell Park Comprehensive Cancer Center Histiocytic Neoplasms, /Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions, Myeloproliferative Neoplasms Thu M. Doan, PharmD, BCOP, of Michigan Rogel Cancer Center Uterine Neoplasms Emily
https://www.nccn.org/compendia-templates/nccn-templates-main/nccn-chemotherapy-order-reviewer-engagementSubmission Request History
Nivolumab for Uterine Neoplasms Submitted by Bristol-Myers Squibb Company on 12/04/2019 Pembrolizumab for Uterine Neoplasms Submitted by Merck & Co., Inc. on 03/19/2020 Pembrolizumab, Pembrolizumab dosing for Uterine Neoplasms Submitted by Merck & Co., Inc. on 04/29/2020 Systemic Therapy Table Headings for Uterine Neoplasms Submitted by GlaxoSmithKline on 05/15/2020, for Uterine Neoplasms Submitted by Merck & Co., Inc. on 06/17/2020 Pembrolizumab
https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-historyAnnual Report 2023
neoplasms. These clinical resources were also translated into Chinese by leading experts in the region
https://www.nccn.org/docs/default-source/about/annual-report-2023.pdf?sfvrsn=8411082_31